Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157

Sikiric P, Seiwerth S, Rucman R, Brcic L, Sever M, Drmic D, et al. · Current Medicinal Chemistry

States plainly that BPC 157, as PL 14736, was 'so far only tested in clinical phase II' for inflammatory bowel disease, with no side effect reported in trials, LD1 not achieved and a negative limit test — the developers' own record that human trials were run.

Population

Review of BPC 157 in inflammatory bowel disease, from the group that developed it

Intervention

n/a

Comparator

n/a

Limitations

A review asserting trial results whose primary reports were never published or peer-reviewed; the Phase II ulcerative-colitis enema result reached only conference abstracts and trade press (Inpharma Weekly, doi 10.2165/00128413-200514930-00023, 2005).